Abstract
Objective The purpose of this report was to analyze black market diversions of atomoxetine, a non-stimulant medication for ADHD, submitted to StreetRx.
Method Data related to black market atomoxetine purchases entered on StreetRx between 2015 and 2019 were analyzed. Data included generic drug name, dosage, purchase price, and date and location in the United States. The mean price per milligram was determined and a heatmap generated.
Results The average price per milligram cost of 113 diverted atomoxetine submissions was $1.35 (± $2.76 SD) (Median = $0.05, Min = $0.01, Max = $20.00). The states with the most submissions included Michigan (11), Pennsylvania (9), Indiana (8), and Ohio (8).
Conclusion Furture qualitative studies should investigate reasons why individuals are motivated to purchase atomoxetine, a non-stimulant medication, on the black market (recreational vs. nootropic vs. other clinical uses).
Competing Interest Statement
BJP was part of an osteoarthritis research team from 2019-2021 supported by Pfizer and Eli Lilly. He receives research support from the Geisinger Academic Clinical Research Center. The other authors have no financial or personal disclosures.
Funding Statement
This study did not receive any external funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research was approved as exempt by the Geisinger IRB.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data in this manuscript may be available. upon request to StreetRx.com.
